Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Pomper

Showing results (371-380 of 525) with videos related to

Pageof 53
Sort By:
Journal of Labelled Compounds & Radiopharmaceuticals|February 12, 2021
Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [<sup>111</sup> In]In-XYIMSR-01 for phase I regulatory approvalRavindra A De Silva, Michael A Gorin, Ronnie C Mease, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical ProstatectomyLiang Dong, Yun Su, Yinjie Zhu, et al.
Cancers|January 21, 2022
Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CTPatrick W Mihatsch, Matthias Beissert, Martin G Pomper, et al.
Science Advances|July 9, 2019
Imaging CAR T cell therapy with PSMA-targeted positron emission tomographyIl Minn, David J Huss, Hye-Hyun Ahn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 5, 2023
SUVPhilipp E Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 28, 2015
Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimatesSangeeta Ray Banerjee, Catherine A Foss, Mrudula Pullambhatla, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 28, 2021
<sup>68</sup>Ga-labeled ODAP-Urea-based PSMA agents in prostate cancer: first-in-human imaging of an optimized agentXiaojiang Duan, Zhen Cao, Hua Zhu, et al.
Journal of Parkinson'S Disease|February 20, 2025
Cortical α4β2-nicotinic acetylcholine receptors and cognitive decline in Parkinson's diseaseKelly A Mills, Hiroto Kuwabara, Yong Du, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 30, 2020
High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CTRudolf A Werner, Thorsten Derlin, Steven P Rowe, et al.
Scientific Reports|May 7, 2021
Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancersHye-Hyun Ahn, Christine Carrington, Yizong Hu, et al.
Pageof 53

Showing results (371-380 of 525) with videos related to

Sort By:
Pageof 53
Journal of Labelled Compounds & Radiopharmaceuticals|February 12, 2021
Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [<sup>111</sup> In]In-XYIMSR-01 for phase I regulatory approvalRavindra A De Silva, Michael A Gorin, Ronnie C Mease, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 30, 2021
The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical ProstatectomyLiang Dong, Yun Su, Yinjie Zhu, et al.
Cancers|January 21, 2022
Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CTPatrick W Mihatsch, Matthias Beissert, Martin G Pomper, et al.
Science Advances|July 9, 2019
Imaging CAR T cell therapy with PSMA-targeted positron emission tomographyIl Minn, David J Huss, Hye-Hyun Ahn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 5, 2023
SUVPhilipp E Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 28, 2015
Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimatesSangeeta Ray Banerjee, Catherine A Foss, Mrudula Pullambhatla, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 28, 2021
<sup>68</sup>Ga-labeled ODAP-Urea-based PSMA agents in prostate cancer: first-in-human imaging of an optimized agentXiaojiang Duan, Zhen Cao, Hua Zhu, et al.
Journal of Parkinson'S Disease|February 20, 2025
Cortical α4β2-nicotinic acetylcholine receptors and cognitive decline in Parkinson's diseaseKelly A Mills, Hiroto Kuwabara, Yong Du, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 30, 2020
High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CTRudolf A Werner, Thorsten Derlin, Steven P Rowe, et al.
Scientific Reports|May 7, 2021
Nanoparticle-mediated tumor cell expression of mIL-12 via systemic gene delivery treats syngeneic models of murine lung cancersHye-Hyun Ahn, Christine Carrington, Yizong Hu, et al.
Pageof 53